جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

478 مُخرَج نتائج البحث عن «Cancer»

مقالوصول مفتوح20256استشهاد· Semantic Scholar

A novel thiadiazole-based dual inhibitor of carbonic anhydrase-IX and epidermal growth factor receptor targeting cancer: A combined in silico and in vitro approach

Journal of Chemical Research · مجلد 49 (6)

The co-expression of epidermal growth factor receptor and carbonic anhydrase-IX in aggressive tumors such as triple-negative breast cancer contributes to therapeutic resistance through proliferative signaling and hypoxia-mediated adaptation. Dual inhibition of these targets represents a promising strategy for overcoming tumor resilience and enhancing treatment efficacy. A novel thiadiazole-based hybrid molecule ( N -(4-(( E )-1-((( Z )-5-acetyl-3-(4-sulfamoylphenyl)-1,3,4-thiadiazol-2(3 H )-ylidene)hydrazono)ethyl)phenyl)benzamide), ASTPB, was rationally designed through pharmacophore modeling, followed by molecular docking and molecular dynamics simulations for 200 ns to assess its dual-binding affinity to epidermal growth factor receptor and carbonic anhydrase-IX. Molecular dynamics simulations confirmed the stability of ASTPB complexes with both epidermal growth factor receptor and carbonic anhydrase-IX, as indicated by stable root mean square deviation values, consistent radius of gyration, and persistent hydrogen bonding, which supported its strong dual-binding affinity. Further quantum chemical analysis via density functional theory supported the electronic stability and reactive potential of ASTPB. In addition, in silico ADMET (Absorption, Distribution, Metabolism, Excretion, and toxicity) predictions indicated low toxicity, a wide safety margin, limited solubility and absorption, and overall favorable metabolic and distribution profiles. ASTPB was synthesized and exhibited potent dual inhibition of carbonic anhydrase-IX and epidermal growth factor receptor, with IC₅₀ values of 0.046 ± 0.007 µM and 0.059 ± 0.009 µM, respectively, comparable to standard inhibitors. In cytotoxicity assays, ASTPB was examined across several cancer cell lines (HePG-2, MCF-7, HCT-116, PC-3, MDA-MB-231), with the greatest efficacy against MDA-MB-231 (IC₅₀ = 18.15 µM) and minimal toxicity toward normal WI-38 cells (IC₅₀ = 72.46 µM). Cell cycle analysis revealed G0/G1 phase arrest, while Annexin V/PI staining indicated early apoptosis in 76.7% of cells. Molecular assays confirmed upregulation of Bax and caspase-3 (3.7-fold each) and downregulation of Bcl-2 (1.97-fold), indicating activation of the intrinsic apoptotic pathway. In conclusion, ASTPB is a promising dual carbonic anhydrase-IX/epidermal growth factor receptor inhibitor with selective cytotoxicity and potent pro-apoptotic activity, particularly in triple-negative breast cancer models. These findings support its potential as a multi-targeted therapeutic lead in the treatment of hypoxia-adapted, epidermal growth factor receptor–driven malignancies.

carbonic anhydrase IXepidermal growth factor receptortriple-negative breast cancerpharmacophore modeling
مراجعةوصول مفتوح20255استشهاد· Semantic Scholar

From biomolecules to breakthroughs: exosomes as next-generation theranostics in female infertility

Frontiers in Cell and Developmental Biology · مجلد 13 · 1605174-1605174

Female infertility and reproductive disorders represent a significant global health challenge, with complex etiologies often linked to impaired cellular communication, inflammation, and tissue dysfunction. Exosomes (EXOs), nanosized extracellular vesicles laden with bioactive molecules, have become recognized as significant transmitters of intercellular signaling in reproductive physiology and pathology. This review comprehensively discusses the dual diagnostic and therapeutic potential of EXOs in addressing female infertility disorders, such as endometriosis, polycystic ovary syndrome (PCOS), primary ovarian insufficiency (POI), Asherman syndrome, and gynecological cancers. We investigate the strategies whereby EXOs govern important activities like endometrial regeneration, folliculogenesis, immune modulation, and angiogenesis, while highlighting their role in restoring ovarian and uterine homeostasis. Advances in exosome isolation techniques, bioengineering strategies (e.g., cargo loading, surface modification), and scaffold-based delivery systems are critically evaluated for their capacity to enhance therapeutic precision and efficacy. Notwithstanding their potential, issues include standardization of isolation protocols, scalability, and long-term safety, which necessitate further research. By integrating molecular insights with translational innovations, this review underscores the clinical implementation of exosome-based therapeutics in revolutionizing reproductive medicine, offering new hope for personalized, non-invasive treatments in female fertility restoration.

exosomesfemale infertilitytheranosticsextracellular vesicles
مراجعةمفتوح (مستودع)20255استشهاد· Semantic Scholar

Olive Oil Polyphenols: A Promising Approach for Cancer Prevention and Therapy

Food Science & Nutrition · مجلد 13 (9) · e70976-e70976

Cancer is emerging as a leading cause of death globally. Considering the disease burden, scientists are working to develop various strategies by exploring natural sources for cancer treatment. The use of olive oil (OO) and its phytochemicals, specifically oleuropein and hydroxytyrosol (HT), as a remedy against various types of cancer is gaining attention among scientists and researchers. The current review aimed to highlight the antioxidant potential and summarize the various pathways and markers involved in the prevention and treatment of different human cancers. The databases, including Google Scholar, PubMed, and Web of Science, were searched to collect relevant data. The studies showed that some markers are specifically linked to particular types of cancers (such as 27-OHC, ATF-2, TNFRSF10B, HER2, and MET, which are linked to breast cancer; iNOS and NO, which are linked to thyroid cancer; GLUT1 and GLUT4, HIF-1α, MCT4, PKM2, PD-1, PD-L1, and CTLA-4, which are linked to colorectal cancer). Olive oil is involved in the management of these markers to prevent and/or treat all types of cancers by upregulating tumor suppressor genes, downregulating oncogenes, and modulating different pathways (PI3K/AKT/mTOR, Wnt/β-catenin, and MAPK). Taken together, it can be concluded that olive oil and its components have prominent potential to cure cancers in the human body. However, further investigations can be carried out to suggest the lethal doses of olive oils as a whole and its phytochemicals individually for the treatment of cancer.

olive oilpolyphenolsoleuropeinhydroxytyrosol
مقالوصول مفتوح20255استشهاد· Semantic Scholar

Resistomycin as a DNA-targeted topoisomerase II inhibitor: Computational and mechanistic insights into its anticancer potential

Journal of Chemical Research · مجلد 49 (5)

Resistomycin, a microbial secondary metabolite, exhibits promising anticancer potential, yet its mechanism of action remains poorly understood. Here, we combined computational and biological assays to investigate its activity against Topoisomerase II (Topo II). Molecular docking predicted strong binding within the Topo II–DNA complex (–20.76 kcal/mol), while 200 ns molecular dynamics simulations confirmed a stable intercalation mode. Energy decomposition revealed van der Waals interactions as the dominant stabilizing force, with persistent hydrophobic and π-stacking contacts to DNA bases. This non-polar binding profile distinguishes resistomycin from classical Topo II inhibitors. In line with these predictions, resistomycin inhibited Topo II activity with an IC₅₀ of 21.48 nM, surpassing doxorubicin (30.16 nM). Cell-based assays further showed selective cytotoxicity across multiple cancer cell lines (IC₅₀ = 45.68–72.30 µM), while mechanistic studies in HCT-116 cells demonstrated dose-dependent apoptosis and G2/M cell cycle arrest. Collectively, these findings identify resistomycin as a potent DNA-intercalating Topo II inhibitor with a unique binding signature, supporting its potential as a scaffold for developing next-generation anticancer agents.

topoisomerase II inhibitorsDNA intercalationmolecular dockingmolecular dynamics simulation
مراجعةوصول مفتوح20255استشهاد· Semantic Scholar

miRNA regulation of the Akt/mTOR pathway in oral squamous cell carcinoma: a focused review

Discover Oncology · مجلد 16 (1) · 1355-1355

Oral squamous cell carcinoma (OSCC) contributes significantly to global cancer mortality, characterized by a progression from hyperplasia to invasive cancer through a series of genetic and epigenetic alterations. Central to this progression is the Akt/mTOR signaling pathway, which regulates cell proliferation and survival. This review examines the role of microRNAs (miRNAs) in modulating the Akt/mTOR pathway and their implications for OSCC. The Akt/mTOR pathway, activated by receptor tyrosine kinases and involving the PI3K/AKT/mTOR complexes, is crucial for tumor cell growth and metabolism. Dysregulation of this pathway is frequently observed in OSCC, leading to increased proliferation, survival, and metastasis. miRNAs, such as miR-21, miR-99, and miR-145, play significant roles in regulating this pathway by influencing key components like Akt and mTOR. These miRNAs can act as oncogenes or tumor suppressors, affecting cancer progression and response to therapy. The review highlights the potential of targeting miRNAs for OSCC treatment, including strategies to restore normal miRNA levels or inhibit aberrant miRNAs. Such targeted therapies offer promise for improving treatment outcomes and overcoming drug resistance in OSCC.

oral squamous cell carcinomamicroRNAAkt/mTOR signalingPI3K/AKT/mTOR pathway
مقالوصول مغلق20255استشهاد· Semantic Scholar

New Thiadiazole‐Benzenesulfonamide Hybrids as Dual B‐Raf/ VEGFR ‐2 Inhibitors With Promising Anti‐Hepatic Cancer Activity

Chemical Biology & Drug Design · مجلد 106 (1) · e70156-e70156

ABSTRACT A new group of thiadiazole‐benzenesulfonamide hybrids was designed, synthesized, and biologically evaluated as potential dual inhibitors targeting B‐Raf and VEGFR‐2 for cancer therapy. The cytotoxic activity of the synthesized derivatives was assessed against HepG2 and Huh7 liver cancer cell lines, where compound 7a exhibited the most potent activity with IC 50 values of 17.89 μM and 25.07 μM, respectively. The kinase inhibition assay revealed that 7a strongly inhibited both B‐Raf (IC 50 = 0.11 μM) and VEGFR‐2 (IC 50 = 0.15 μM), surpassing sorafenib in B‐Raf inhibition. Further mechanistic studies revealed that 7a induced G2/M phase arrest, with a significant increase in late apoptotic cells (57.08%) compared to the control group (0.15%), confirming its pro‐apoptotic effect. The apoptotic pathway was further validated by caspase‐3 activation, Bax upregulation, and Bcl‐2 downregulation. Computational analyses verified the effective binding of compound 7a to VEGFR‐2. These analyses included molecular docking, molecular dynamic (MD) simulations, molecular mechanics with generalized Born and surface area solvation (MM‐GBSA), protein‐ligand interaction fingerprints (ProLIF), principal component analysis (PCAT), and free energy landscape (FEL) studies. Additionally, DFT studies indicated 7a 's stability and reactivity. In silico ADMET predictions indicated that the derivatives had good absorption, were non‐mutagenic, non‐carcinogenic, and exhibited low toxicity risks compared to sorafenib. These findings suggest that the synthesized thiadiazole‐benzenesulfonamide hybrids, particularly 7a , represent promising dual BRAF/VEGFR‐2 inhibitors with potent anti‐cancer activity, warranting further optimization and preclinical evaluation.

BRAF inhibitorsVEGFR-2 inhibitorsdual kinase inhibitorsliver cancer
مقالمفتوح (مستودع)20255استشهاد· Semantic Scholar

Anti-breast cancer potential of thieno-pyrimidine derivatives as VEGFR-2 inhibitors

Future Medicinal Chemistry · مجلد 17 (7) · 803-818

Background Thieno-pyrimidine derivatives have emerged as promising candidates for VEGFR-2 inhibition. This study aimed to design, synthesize, and evaluate novel thieno-pyrimidine derivatives for their anti-cancer potential.Methods A series of thieno-pyrimidine compounds were synthesized and screened for in vitro cytotoxicity against MDA-231 and MCF-7 cell lines. The most active compound, 6b, was further analyzed for VEGFR-2 kinase inhibition, wound healing, apoptosis induction, and cell cycle arrest. Molecular docking, 200 ns molecular dynamics simulations, MM-GBSA, ProLIF PCAT, and FEL analyses were conducted to assess binding stability. DFT calculations evaluated electronic properties, while in silico ADMET profiling predicted pharmacokinetics and toxicity.Results Compound 6b exhibited potent cytotoxicity with IC50 values of 5.91 µM (MDA-231) and 7.16 µM (MCF-7). It demonstrated VEGFR-2 inhibition is comparable to sorafenib (IC50: 53.63 ± 3.14 nM). Wound healing assays showed significant inhibition of MDA-231 migration. Flow cytometry confirmed apoptosis induction (57.20% early apoptosis) and G1 phase arrest. Gene expression analysis revealed upregulation of pro-apoptotic markers and downregulation of Bcl-2. Computational studies confirmed stable VEGFR-2 binding, and ADMET predictions indicated a favorable safety profile.Conclusion Compound 6b exhibits strong VEGFR-2 inhibition, potent anti-cancer effects, and a favorable toxicity profile, highlighting its potential for further therapeutic development.

VEGFR-2 inhibitorsbreast canceranticancer agentscytotoxicity
مقالوصول مفتوح20255استشهاد· Semantic Scholar

Integrated in silico and in vitro exploration of the anti-VEGFR-2 activities of a semisynthetic xanthine alkaloid inhibiting breast cancer

PLoS ONE · مجلد 20 (1) · e0316146-e0316146

This study presents T-1-NBAB, a new compound derived from the natural xanthine alkaloid theobromine, aimed at inhibiting VEGFR-2, a crucial protein in angiogenesis. T-1-NBAB's potential to interacts with and inhibit the VEGFR-2 was indicated using in silico techniques like molecular docking, MD simulations, MM-GBSA, PLIP, essential dynamics, and bi-dimensional projection experiments. DFT experiments was utilized also to study the structural and electrostatic properties of T-1-NBAB. Computational analysis was performed to predict the ADME-Tox profiles of T-1-NBAB. After semisynthesis, the in vitro results showed that T-1-NBAB effectively inhibits VEGFR-2, with an IC50 of 0.115 μM, compared to sorafenib's 0.0591 μM. In vitro tests also demonstrated significant activity of T-1-NBAB against breast cancer cell lines MCF7 and T47D, with IC50 values of 16.88 μM and 61.17 μM, respectively, and high selectivity. Importantly, T-1-NBAB induced early and late apoptosis in MCF7 cells, indicating its potential as a strong anticancer agent. Additionally, T-1-NBAB reduced the migration and healing abilities of MCF7 cells, suggesting it could be a promising anti-angiogenic agent. Overall, these findings suggest that T-1-NBAB is a promising lead compound for further research as a potential treatment for breast cancer.

xanthine alkaloidstheobromine derivativesVEGFR-2 inhibitionangiogenesis inhibitors
مقالوصول مغلق20254استشهاد· Semantic Scholar

Design, Computational, Synthesis, and Anti-Cancer Evaluation of a Multifunctional 2,3-Dihydro-1,3,4-Thiadiazole-Benzenesulfonamide Hybrid as a Triple Inhibitor of CAIX, CAXII, and EGFR

Journal of Computational Biophysics and Chemistry · مجلد 25 (11) · 2559-2583

A novel 2,3-dihydro-1,3,4-thiadiazole-benzenesulfonamide hybrid, N-(4-(([Formula: see text]-1-((([Formula: see text]-5-acetyl-3- (4-sulfamoylphenyl)-1,3,4-thiadiazol-2(3H)-ylidene)hydrazono)ethyl)phenyl)-4-chloro benzamide (N-ASTPC), was rationally designed as a triple inhibitor targeting carbonic anhydrase IX (CAIX), carbonic anhydrase XII (CAXII), and the epidermal growth factor receptor (EGFR) — key targets overexpressed in cancer. Molecular docking and 200-ns molecular dynamics (MD) simulations confirmed stable and high-affinity interactions of N-ASTPC with the active sites of all three targets. MM-GBSA binding free energy calculations and ProLIF interaction profiling further supported these findings, while principal component analysis (PCA) revealed limited conformational drift, indicating robust complex formation. Additionally, density functional theory (DFT) assessments affirmed N-ASTPC’s electronic stability and favorable reactivity. Biological assays demonstrated potent inhibitory activity with IC 50 values of 0.039 [Formula: see text]M, 0.04 [Formula: see text]M, and 0.05 [Formula: see text]M for CAIX, CAXII, and EGFR, respectively, comparable or superior to standard inhibitors (acetazolamide and erlotinib). Regarding in vitro cytotoxicity, N-ASTPC displayed selective toxicity toward cancer cells over normal fibroblasts, with notable effects in MDA-MB-231 and MCF-7 breast cancer lines compared to doxorubicin. Flow cytometry showed that N-ASTPC induces significant S-phase arrest and robust early apoptosis, confirmed by a [Formula: see text]5.7-fold increase in Bax, [Formula: see text]4.5-fold increase in caspase-3, and [Formula: see text]2-fold decrease in Bcl-2 expression — consistent with mitochondrial apoptotic pathway activation. Collectively, these findings establish N-ASTPC as a promising multifunctional anti-cancer lead compound capable of simultaneously disrupting tumor cell metabolism and signaling via CAIX, CAXII, and EGFR inhibition. Its multi-modal mechanism and selective apoptotic induction underscore its potential for further preclinical development, particularly in hypoxic and triple-negative breast cancer models.

carbonic anhydrase IXcarbonic anhydrase XIIepidermal growth factor receptoranticancer drug design
مقالوصول مفتوح20254استشهاد· Semantic Scholar

Exploring the Anticancer Potential of Chitosome-Encapsulated Theobromine Analogue: Integrated Computational, Physiochemical and In vitro Study

Natural Product Communications · مجلد 20 (10)

Background Theobromine derivatives have emerged as promising anticancer agents, but their therapeutic potential is limited by poor bioavailability. This study investigates a chitosome-based delivery system for a novel theobromine derivative, N -(4-Chlorophenyl)-2-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1 H -purin-1-yl)acetamide ( T-1-PCPA ), to evaluate its anticancer potential. Methods T-1-PCPA -loaded chitosomess ( T-1-PCPA loaded chitosomes) were formulated using the thin film hydration technique. Molecular docking was employed to computationally assess the stability of the T-1-PCPA loaded chitosomes. Experimentally, various physicochemical properties, including particle size, polydispersity index (PDI), zeta potential, and entrapment efficiency, were analyzed. Transmission electron microscopy (TEM) was used to investigate morphological features. In vitro , the cytotoxicity of the T-1-PCPA -PC-CS was evaluated on HCT-116 and A549 cancer cell lines. Further mechanistic studies included cell cycle analysis, apoptosis detection, and cell migration assays were performed. Results The T-1-PCPA loaded chitosomes exhibited good colloidal stability, with well-defined spherical particles averaging 142.6 ± 4.3 nm in size, a zeta potential of +32.4 ± 1.6 mV, and an entrapment efficiency of 89.2 ± 2.1%, indicating efficient drug loading and formulation stability. In vitro cytotoxicity assays revealed significantly enhanced anticancer activity, with IC 50 values of 8.05 ± 0.06 μg/mL for HCT-116 and 9.55 ± 0.15 μg/mL for A549 cells—substantially lower than those of free T-1-PCPA and blank formulations. Flow cytometric cell cycle analysis demonstrated arrest at G0-G1 and S phases, while apoptosis analysis revealed a significant increase in total apoptosis (39.55%) in treated HCT-116 cells. Cell migration assays showed a 63.4% reduction in migration compared to control, supporting the formulation's anti-migratory potential. Conclusion T-1-PCPA -loaded chitosomes system shows strong potential as a targeted anticancer nanotherapy, demonstrating enhanced cytotoxicity, apoptosis induction, cell cycle arrest, and anti-migratory activity. With high drug loading, stability, and selectivity toward cancer cells, it addresses key limitations of conventional chemotherapy. These findings warrant further preclinical evaluation for colorectal and lung cancer treatment.

chitosomestheobromine derivativesanticancer drug deliverydrug encapsulation
مقالوصول مغلق20254استشهاد· Semantic Scholar

New 1,3,4‐Thiadiazole‐Based Dual B‐Raf/VEGFR‐2 Inhibitors With Potential Anti‐Breast Activity: Design, Synthesis, In Vitro and In Silico Evaluations

Archiv der Pharmazie · مجلد 358 (9) · e70097-e70097

This study reports the design, synthesis, and biological evaluation of a novel series of 1,3,4-thiadiazole-based derivatives as dual B-Raf and VEGFR-2 kinase inhibitors with potential anticancer activity. Among the synthesized compounds, 7b emerged as the most potent candidate, exhibiting strong cytotoxicity against the MDA-MB-231 and MCF-7 breast cancer cell lines (IC₅₀ = 9.66 and 15.83 µM, respectively), with minimal toxicity toward normal WI-38 and WISH cells, reflected by favorable selectivity indices. Compound 7b, featuring a unique structural assembly of a 2,3-dihydro-1,3,4-thiadiazole core, a para-methoxyphenyl group, and a sulfonamide-linked methylpiperidine moiety, exhibited superior dual-inhibitory activity. It showed IC₅₀ values of 0.75 µM for B-Raf and 58.13 nM for VEGFR-2. Flow cytometry and gene expression analysis revealed that 7b induces G1-phase cell-cycle arrest and promotes apoptosis through the upregulation of BAX, caspases-8/9, and downregulation of Bcl-2. Compound 7b also inhibited cell migration in wound-healing assays. Structure-activity relationship (SAR) analysis indicated that para-substituted electron-donating groups enhanced cytotoxic potency. Molecular docking and molecular dynamics simulations confirmed the stable binding of 7b to the kinase active sites, supported by favorable Glide scores (-25.47 kcal/mol for VEGFR-2 and -31.64 kcal/mol) and MM-GBSA (molecular mechanics with generalized Born and surface area solvation) binding energies. Density functional theory (DFT) calculations further validated the compound's electronic stability and reactivity. These integrated findings suggest that compound 7b is a promising lead for further development as a selective dual kinase inhibitor for breast cancer therapy.

1,3,4-thiadiazole derivativesVEGFR-2 inhibitorsdual kinase inhibitorsbreast cancer
مقالمفتوح (مستودع)20254استشهاد· Semantic Scholar

Unveiling a sustainable approach to cancer treatment: the antitumor activity of amygdalin and cell-free supernatant of Lacticaseibacillus rhamnosus

Folia Microbiologica · مجلد 71 (4) · 863-874

The pharmaceutical industry increasingly prioritizes environmental sustainability across its strategies, focusing on developing eco-friendly anti-cancer treatments. This is particularly important considering many anti-cancer drugs are not fully metabolized and pollute aquatic ecosystems. Amygdalin, a plant-derived compound, and cell-free supernatants (CFS) of Lacticaseibacillus rhamnosus show promise as sustainable anti-cancer agents. This study evaluated the potential anti-cancer activity of amygdalin and L. rhamnosus CFS against MCF-7 and A549 cancer cell lines. Cell viability was assessed using the MTT assay in response to monotherapy and combination therapy treatments. The induction of apoptosis was investigated using flow cytometric analyses. The combination demonstrated a synergistic effect on MCF-7 and A549 cell lines, with a combination index (CI) value of 0.8159 ± 0.0245 and 0.6422 ± 0.0316, respectively. Further analysis using propidium iodide (PI) staining and Annexin V confirmed increased apoptosis in combination-treated cells compared to those treated with amygdalin alone. These findings suggest that the combination of amygdalin and CFS of L. rhamnosus exhibits a synergistic anti-cancer effect against MCF-7 and A549 cells. Therefore, this combination is considered sustainable, eco-friendly, and effective anti-cancer treatment. This is the first study to investigate the anti-cancer effect of amygdalin in combination with L. rhamnosus cell-free supernatant (CFS) while considering its potential for environmental sustainability. Further research in a xenograft animal model is warranted to validate these findings.

amygdalinLactobacillus rhamnosuscell-free supernatantanticancer activity